PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1364756
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1364756
The global clinical trial supplies market size is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9% during the forecast period. Factors such as Increasing number of clinical trials, Growing product pipeline, and Increasing decentralization of clinical trials are likely to have positive impact on the market growth.
Scope of the Report | |
---|---|
Years Considered for the Study | 2021-2028 |
Base Year | 2022 |
Forecast Period | 2023-2028 |
Units Considered | Value (USD) billion |
Segments | By Service, By Phase, By Type, By Therapeutic Area, By End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. |
"The logistics and distribution segment held the dominant share in the clinical trial supplies market"
Based on services, the global clinical trial supplies market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.
"Phase II segment accounted for the largest share of the phase segment in 2022."
Based on phase, the clinical trial supplies market is segmented into phase I, phase II, phase III, phase IV, BA/BE studies. In 2022, the phase II segment accounted for the largest share of the clinical trial supplies market. The segment held the dominant share in the market owing to various factors such as increasing the number of registration in clinical trials and the rising R&D investment by pharmaceutical and biotechnologies company for new cancer drug development.
"Asia Pacific region is likely to grow at a faster pace in the clinical trial supplies market."
The clinical trial supplies market region is segmented into North America, Europe, Asia Pacific, Latin America Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing number of registered clinical trials. The increasing decentralization of clinical trials from China, India, and Japan due to presence of prominent players are engaged in providing services for clinical trial, supports market growth in the Asia Pacific.
This report provides a detailed picture of the clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments, such as service, phase, type, therapeutic area, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US),